The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic...

ver descrição completa

Detalhes bibliográficos
Autores: Bocchetta, M, Galluzzi, S, Kehoe, PG, Aguera, E, Bernabei, R, Bullock, R, Ceccaldi, M, Dartigues, JF, de Mendonca, A, Didic, M, Eriksdotter, M, Felician, O, Frolich, L, Gertz, HJ, Hallikainen, M, Hasselbalch, SG, Hausner, L, Heuser, I, Jessen, F, Jones, RW, Kurz, A, Lawlor, B, Lleo, A, Martinez-Lage, P, Mecocci, P, Mehrabian, S, Monsch, A, Nobili, F, Nordberg, A, Rikkert, MO, Orgogozo, JM, Pasquier, F, Peters, O, Salmon, E, Sanchez-Castellano, C, Santana, I, Sarazin, M, Traykov, L, Tsolaki, M, Visser, PJ, Wallin, AK, Wilcock, G, Wilkinson, D, Wolf, H, Yener, G, Zekry, D, Frisoni, GB
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2015
País:España
Recursos:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositório:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p14638
Acesso em linha:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=14638
http://edoc.unibas.ch/41181/
Access Level:Acceso aberto
Palavra-chave:Biomarkers
Alzheimer's disease
Mild cognitive impairment
Diagnosis
Descrição
Resumo:We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid position emission tomography [PET], cerebrospinal fluid [CSF] A beta 42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it "always/frequently") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as "moderate". Seventy-nine percent of responders felt "very/extremely" comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P < .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Registros relacionados